Provectus Biopharmaceuticals, Inc.
General ticker "PVCT" information:
- Sector: Health Care
- Industry: Pharmaceuticals
- Capitalization: $38.9M (TTM average)
Provectus Biopharmaceuticals, Inc. does not follow the US Stock Market performance with the rate: -29.4%.
Estimated limits based on current volatility of 6.3%: low 0.06$, high 0.07$
Factors to consider:
- Total employees count: 4 as of 2022
- Company does not operate outside North America (retrieved using AI)
- Top business risk factors: Operational and conduct risks, Financing risks, Regulatory and compliance, Market competition, Labor/talent shortage/retention
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [0.07$, 0.20$]
- 2025-12-31 to 2026-12-31 estimated range: [0.07$, 0.20$]
Financial Metrics affecting the PVCT estimates:
- Positive: with PPE of -10.9 at the end of fiscal year the price was very low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -6.35 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Negative: negative Net income
- Negative: Shareholder equity ratio, % of -592.20 <= 18.93
- Positive: Interest expense per share per price, % of 0.46 <= 0.79
Short-term PVCT quotes
Long-term PVCT plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.99MM | $0.56MM | $0.62MM |
| Operating Expenses | $4.42MM | $3.46MM | $4.57MM |
| Operating Income | $-3.43MM | $-2.90MM | $-3.95MM |
| Non-Operating Income | $-0.13MM | $-0.20MM | $-0.82MM |
| Interest Expense | $0.16MM | $0.22MM | $0.24MM |
| R&D Expense | $2.39MM | $1.75MM | $1.99MM |
| Income(Loss) | $-3.55MM | $-3.10MM | $-4.77MM |
| Taxes | $0.00MM | $0.00MM | $-0.01MM |
| Profit(Loss)* | $-3.55MM | $-3.10MM | $-4.73MM |
| Stockholders Equity | $-6.23MM | $-7.59MM | $-5.96MM |
| Assets | $2.04MM | $1.45MM | $1.01MM |
| Operating Cash Flow | $-3.04MM | $-2.57MM | $-3.28MM |
| Capital expenditure | $0.00MM | $0.00MM | $0.00MM |
| Investing Cash Flow | $-0.00MM | $-0.02MM | $0.00MM |
| Financing Cash Flow | $1.37MM | $2.19MM | $2.75MM |
| Earnings Per Share** | $-0.01 | $-0.01 | $-0.01 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.